Key result
In patients with VLST-4bAMI, no significant difference in major cardiovascular events was observed between Re-stent, DCB, and POBA at 1 year follow-up.
Why the study?
To compare different interventional treatment strategies in the real world for patients with type 4b acute myocardial infarction caused by very late stent thrombosis.
Do different interventional strategies (Re-stent, DCB, POBA) improve 1-year MACE in patients with type 4b acute myocardial infarction caused by very late stent thrombosis?
Do different interventional strategies (Re-stent, DCB, POBA) improve 1-year MACE in patients with type 4b acute myocardial infarction caused by very late stent thrombosis?
In real-world patients with type 4b AMI due to very late stent thrombosis, drug-coated balloons, re-stenting, and plain balloon angioplasty yielded similar 1-year MACE rates, though POBA was associated with higher target lesion revascularization.
Answers are grounded in this paper and cite their sources.
No MACE difference among strategies in VLST-4bAMI; hypothesis-generating and requires randomized trials before guiding practice.
To compare different interventional strategies for patients with 4b-AMI because of very late stent thrombosis (VLST) in real world. 316 patients with VLST-4bAMI were enrolled and divided into Re-stent group, drug coated balloon (DCB) group and plain old balloon angioplasty(POBA) group. The MACE was observed at 1 year follow up including cardiac death, recurrent AMI(re-AMI), target lesion revascularization (TLR) and recurrent ST(RST). The Kaplan-Meier survival curves were used to compare the survival of free-MACE events, and the propensity score matching was used for further analysis. 66 MACEs were observed at 1 year follow-up. There was no significant difference in the MACE between the three groups (P > 0.05), but TLR in the POBA group was the highest (P = 0.023). Kaplan-Meier survival analysis showed that there was no significant difference in the survival of 1-year cumulative free-MACE events between the three groups (P > 0.05), the survival of free-TLR in the POBA group was the lowest (P = 0.015). There was no significant difference in the incidence of MACE after propensity score matching. There is no significant difference in prognosis between the three interventional treatment strategies of VLST-4bAMI. DCB did not have less favorable clinical outcomes than Re-stent or POBA.The treatment of VLST-4bAMI is still a major clinical challenge.
No takes yet. Share an insight, caveat, or question.
Li et al. (2025) studied this question. In patients with VLST-4bAMI, no significant difference in major cardiovascular events was observed between Re-stent, DCB, and POBA at 1 year follow-up.
Synapse has enriched 10 related papers. Consider them for comparative context: